Homeopathic treatment of white patch

Phase 3

Completed

• Conditions: Vitiligo,

• Registration Number: CTRI/2018/10/016160
• Lead Sponsor: National Institute of Homoeopathy

Brief Summary

Vitiligo  is an  acquired  de-pigmentation  disorder characterized  by  loss of  melanocytes  from epidermis. Worldwide  prevalence of  Vitiligo  ranges is 0.4  and  2% and in India the relative  prevalence varied  between  0.46 and  8.8%. Studies reveals apositive role of homoeopathy in Vitiligo  where   varying   degrees  of   repigmentation   was reported. In this prospective, doubleblind, randomised, placebo controlled, parallel arm trial at National Instituteof Homoeopathy, 60 patients suffering from vitiligo will be randomised in 1:1ratio into either individualised homeopathic medicines in 50 millesimal scaleor identical placebo. VASI will be used as the primary outcome measure and VitiQoLquestionnaire and DLQI as secondary outcome measures, measured at baseline, 3rdmonth and 6th month. At the end of 6 months, comparative analysiswill be carried out to detect group differences, if any. Results will bepublished in scientific journals.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-11
• Last Update Posted: 2020-09-22

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Suffering from Vitiligo for at least last 3 months 2.
• Patients of both sexes 3.
• Age between 18-65 years 4.
• Literate; able to read English and/or Bengali 5.
• Patients who have not taken any treatment since last 2 weeks for Vitiligo.

Exclusion Criteria

• Patients who are too sick for consultation 2.
• Unwilling to take part and not giving consent to join the study 3.
• Unable to read patient information sheet 4.
• Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life- threatening illness affecting quality of life or any organ failure 5.
• Pregnancy and lactation 6.
• Substance abuse and/or dependence 7.
• Self-reported immune-compromised state 8.
• Undergoing homoeopathic treatment for any chronic disease within last 6 months.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Vitiligo area scoring index (VASI) evaluateing disease extent and severity	At baseline, 3rd month and 6th month

Secondary Outcome Measures

Name	Time	Method
Vitiligo Specific Health Related Quality of Life Instrument (VitiQOL)	At baseline, 3rd month and 6th month
Dermatological Life Quality Index (DLQI) questionnaire	At baseline, 3rd month and 6th month

Trial Locations

Locations (1)

National Institute of Homoeopathy; 🇮🇳 Kolkata, WEST BENGAL, India

National Institute of Homoeopathy

🇮🇳Kolkata, WEST BENGAL, India

K Avaranjika

Principal investigator

8778968586

kannanavaranjika@gmail.com